Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 10Esophageal Squamous Cell Carcinoma 4Carcinoma, Hepatocellular 4Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2HER2-positive Gastric Cancer 2Colonic Neoplasms 2Breast Neoplasms 2Stage IA Pancreatic Adenocarcinoma 1Mouth Neoplasms 1Malignant Neoplasms of Digestive Organs 1Immunotherapy 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Fruquintinib 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Extrapancreatic Neuroendocrine Tumor 1Esophageal Neoplasms 1Efficacy and Safety 1Drug-Related Side Effects and Adverse Reactions 1Biliary Tract Neoplasms 1Advanced Pancreatic Cancer 1Advanced Biliary Tract Carcinoma 1Adenoma, Islet Cell 1Adenocarcinoma 1

Interventions

irinotecan sucrosofate 1apatinib 1Temozolomide 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Efficacy and Safety × Tegafur × Clear all
NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡